Ava Begins Evaluation of its Fertility Tracking Sensor Bracelet in COVID-19 Detection
By Michael Barbella, Managing Editor | 04.27.21
Pilot study data shows Ava's algorithm accurately detected 71 percent of COVID-19 positive infections two days before symptom onset.
Digital healthcare company Ava is testing whether its fertility tracking algorithm technology is also effective at detecting COVID-19 infections in real-time.
Other studies to date—including the COVI-GAPP trial Ava announced in April 2020—have examined the feasibility of using machine learning and wearable devices to retrospectively detect COVID-19 infection, but the first-of-its-kind COVID-19: Rapid Early Detection (COVID-RED) clinical trial takes this research to the next step: testing real-life, real-time efficacy of Ava's device (currently used primarily for fertility tracking) in helping stop the spread of the virus during its pre-symptomatic phase. Researchers will evaluate how well the bracelet and complementary app identify a COVID-19 infection prior to symptom onset.
In a retrospective analysis of data from the COVI-GAPP pilot trial, Ava's COVID-19 infection detection algorithm was shown to accurately detect 71 percent of COVID-19 positive infections two days prior to symptom onset. Ava expects the algorithm to perform similarly in the initial phase of the COVID-RED study, and iterative updates to the algorithm are planned through 2021 to further improve its accuracy.
In addition, Ava is the only wearable currently leveraged in the fight against COVID-19 designed with a deep understanding of the science behind female physiology—a unique advantage, since researchers will be able to take menstrual cycle changes in multiple physiological parameters including skin temperature into account to prevent reporting false positives.
"This is a real breakthrough in the early detection of COVID-19 infection and in the fight against the pandemic," said Dr. Lorenz Risch. "Because one of the big challenges is to identify virus carriers as early as possible. A lot of people who catch COVID-19 only show symptoms days afterwards, so the virus is often passed on unknowingly, which aids its spread and makes effective tracking difficult. The situation has been made even more difficult by the emergence of virus mutations that seem to spread more quickly from person to person than the original strain. Early detection is therefore increasingly important."
More than 20,000 participants of all genders and across general and high-risk populations will be provided with an Ava bracelet in the study, which began recruiting in February and is expected to run through December 2021.
Participants will wear the Ava bracelet for up to nine months nightly while they sleep; upon waking, they will be able to see an AI-generated indicator reflecting their overall health status. The underlying algorithm, based on changes in their physiological parameters over the preceding few days and/or self-reported symptoms, will display one of three possible indicators: no change in wellness detected; some minor changes in symptoms detected with the suggestion to stay home and self-isolate; or, changes in symptoms and/or biophysical data detected that could signal a potential COVID-19 infection. Partnering with other consortium members like Roche and Sanquin, Ava will provide asymptomatic participants identified as potentially ill by the app with access to a diagnostic test, ideally enabling them to self-isolate and prevent infecting others.
"Ava has helped tens of thousands of women around the world conceive and start families since launching in 2016. Now we are taking the power of our scientific expertise and technology to join in the fight against COVID-19 in a way no other wearable medical device has yet -- by testing our infection detection algorithm in real-time, providing bracelet wearers with daily updates about their health and well-being," said Ava CEO and Co-founder Lea von Bidder. "We believe our deep understanding of female physiology gives us a unique advantage over other wearables in helping solve this global health challenge."
According to von Bidder, Ava's COVID-19 initial infection detection algorithm was trained on data from almost 500 women using the Ava Fertility Tracker who reported an infection in-app: "While historically medical research has relied on data and research using male participants then generalized to women, we are flipping the script at Ava—understanding women's physiology first, then adapting algorithms to generalize to the whole population."
Funded by the Innovative Medicines Initiative 2 Joint Undertaking, the COVID-RED consortium is a collaboration bringing together global experts in public health, epidemiology, biomedical informatics, wearable sensor technology, and machine learning from the private and public sectors. Members of the consortium include Ava, Julius Clinical Research, Labormedizinisches Zentrum Dr Risch Ostschweiz, Roche Diagnostics Nederland (Roche), Stichting Sanquin Bloedvoorziening (Sanquin), Takeda Pharmaceuticals International (Takeda), University College London (UCL), Universitair Medisch Centrum Utrecht (UMC Utrecht), and Vive.
* The Ava Fertility Tracker is the only U.S. Food and Drug Administration-cleared fertility tracking wearable and is also CE-marked according to MDD 93/42/EC for the purpose of measuring and displaying physiological parameters to facilitate conception and to provide general information on health and wellness to users.
Other studies to date—including the COVI-GAPP trial Ava announced in April 2020—have examined the feasibility of using machine learning and wearable devices to retrospectively detect COVID-19 infection, but the first-of-its-kind COVID-19: Rapid Early Detection (COVID-RED) clinical trial takes this research to the next step: testing real-life, real-time efficacy of Ava's device (currently used primarily for fertility tracking) in helping stop the spread of the virus during its pre-symptomatic phase. Researchers will evaluate how well the bracelet and complementary app identify a COVID-19 infection prior to symptom onset.
In a retrospective analysis of data from the COVI-GAPP pilot trial, Ava's COVID-19 infection detection algorithm was shown to accurately detect 71 percent of COVID-19 positive infections two days prior to symptom onset. Ava expects the algorithm to perform similarly in the initial phase of the COVID-RED study, and iterative updates to the algorithm are planned through 2021 to further improve its accuracy.
In addition, Ava is the only wearable currently leveraged in the fight against COVID-19 designed with a deep understanding of the science behind female physiology—a unique advantage, since researchers will be able to take menstrual cycle changes in multiple physiological parameters including skin temperature into account to prevent reporting false positives.
"This is a real breakthrough in the early detection of COVID-19 infection and in the fight against the pandemic," said Dr. Lorenz Risch. "Because one of the big challenges is to identify virus carriers as early as possible. A lot of people who catch COVID-19 only show symptoms days afterwards, so the virus is often passed on unknowingly, which aids its spread and makes effective tracking difficult. The situation has been made even more difficult by the emergence of virus mutations that seem to spread more quickly from person to person than the original strain. Early detection is therefore increasingly important."
More than 20,000 participants of all genders and across general and high-risk populations will be provided with an Ava bracelet in the study, which began recruiting in February and is expected to run through December 2021.
Participants will wear the Ava bracelet for up to nine months nightly while they sleep; upon waking, they will be able to see an AI-generated indicator reflecting their overall health status. The underlying algorithm, based on changes in their physiological parameters over the preceding few days and/or self-reported symptoms, will display one of three possible indicators: no change in wellness detected; some minor changes in symptoms detected with the suggestion to stay home and self-isolate; or, changes in symptoms and/or biophysical data detected that could signal a potential COVID-19 infection. Partnering with other consortium members like Roche and Sanquin, Ava will provide asymptomatic participants identified as potentially ill by the app with access to a diagnostic test, ideally enabling them to self-isolate and prevent infecting others.
"Ava has helped tens of thousands of women around the world conceive and start families since launching in 2016. Now we are taking the power of our scientific expertise and technology to join in the fight against COVID-19 in a way no other wearable medical device has yet -- by testing our infection detection algorithm in real-time, providing bracelet wearers with daily updates about their health and well-being," said Ava CEO and Co-founder Lea von Bidder. "We believe our deep understanding of female physiology gives us a unique advantage over other wearables in helping solve this global health challenge."
According to von Bidder, Ava's COVID-19 initial infection detection algorithm was trained on data from almost 500 women using the Ava Fertility Tracker who reported an infection in-app: "While historically medical research has relied on data and research using male participants then generalized to women, we are flipping the script at Ava—understanding women's physiology first, then adapting algorithms to generalize to the whole population."
Funded by the Innovative Medicines Initiative 2 Joint Undertaking, the COVID-RED consortium is a collaboration bringing together global experts in public health, epidemiology, biomedical informatics, wearable sensor technology, and machine learning from the private and public sectors. Members of the consortium include Ava, Julius Clinical Research, Labormedizinisches Zentrum Dr Risch Ostschweiz, Roche Diagnostics Nederland (Roche), Stichting Sanquin Bloedvoorziening (Sanquin), Takeda Pharmaceuticals International (Takeda), University College London (UCL), Universitair Medisch Centrum Utrecht (UMC Utrecht), and Vive.
* The Ava Fertility Tracker is the only U.S. Food and Drug Administration-cleared fertility tracking wearable and is also CE-marked according to MDD 93/42/EC for the purpose of measuring and displaying physiological parameters to facilitate conception and to provide general information on health and wellness to users.
